The differences in immune cell infiltration scores, PD-1 and PD-L1 expression levels, as well as tumor mutation burden between the high-risk and low-risk subgroups suggested that high-risk patients may be more suitable candidates for immunotherapy. The gene discussed is CD274; the disease is neoplasm.